PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 152 filers reported holding PDL BIOPHARMA INC in Q4 2019. The put-call ratio across all filers is 0.33 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $511,000 | +126.1% | 162,336 | +108.9% | 1.19% | +162.3% |
| Q2 2020 | $226,000 | +4.1% | 77,707 | +1.2% | 0.45% | -1.7% |
| Q1 2020 | $217,000 | -16.5% | 76,788 | -4.1% | 0.46% | -10.5% |
| Q4 2019 | $260,000 | +47.7% | 80,063 | -2.0% | 0.52% | +33.4% |
| Q3 2019 | $176,000 | -34.3% | 81,713 | -4.3% | 0.39% | -41.0% |
| Q2 2019 | $268,000 | -15.7% | 85,368 | 0.0% | 0.65% | +6.2% |
| Q1 2019 | $318,000 | +31.4% | 85,368 | +2.4% | 0.62% | +25.5% |
| Q4 2018 | $242,000 | -1.6% | 83,359 | -11.0% | 0.49% | +16.4% |
| Q3 2018 | $246,000 | +26.2% | 93,708 | +12.4% | 0.42% | +33.5% |
| Q2 2018 | $195,000 | -17.7% | 83,369 | +3.3% | 0.32% | -13.7% |
| Q1 2018 | $237,000 | +8.2% | 80,722 | +1.0% | 0.37% | -0.5% |
| Q4 2017 | $219,000 | – | 79,937 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |